1. Impact of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) on Birth Defects: A Systematic Review and Meta-Analysis
- Author
-
Adriana Renzi, Felipe Dieamant, Camila Zamara, A. Nicoletti, Laura D. Vagnini, Fabiana C. Massaro, Bruna Petersen, Jose G. Franco, Claudia G. Petersen, Antonio Hélio Oliani, Joao Batista A. Oliveira, and Juliana Ricci
- Subjects
Male ,medicine.medical_specialty ,Pregnancy Rate ,Reproductive Techniques, Assisted ,medicine.medical_treatment ,Intracytoplasmic sperm injection ,Sperm injection ,Pregnancy ,Humans ,Medicine ,Sperm Injections, Intracytoplasmic ,Child ,Assisted reproductive technology ,Intracytoplasmic Morphologically Selected Sperm Injection ,urogenital system ,business.industry ,Obstetrics ,Incidence (epidemiology) ,Infant, Newborn ,medicine.disease ,Spermatozoa ,Sperm ,meta-analysis ,birth defects ,Neonatal outcomes ,Meta-analysis ,IMSI ,IVI ,Original Article ,Female ,business ,Trisomy - Abstract
Objective It is generally accepted that the incidence of birth defects in spontaneously conceived children ranges between 2.0-4.0%. However, several studies have shown that babies born after assisted reproductive technology (ART) procedures tend to present more congenital malformations than naturally conceived children, with 6.5% of the children born after intracytoplasmic sperm injection (ICSI) presenting birth defects. The use of high magnification sperm selection before ICSI was introduced in the early 2000s to allow the identification of spermatozoa with low risk of sperm DNA damage. Intracytoplasmic morphologically selected sperm injection (IMSI) is expected to change the incidence of congenital malformations, although data on the incidence of birth defects in children conceived after IMSI are still scarce. Methods A systematic review based on searches performed in electronic databases (PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane Central Register of Controlled Trials) including articles published by February 2021 was conducted to identify trials comparing the neonatal outcomes of ICSI and IMSI. The outcome measured was the rate of birth defects in children born after ICSI or IMSI. Three trials were included as targets for data extraction and meta-analysis. Results Our meta-analysis included 3907 children conceived after IMSI (1280) or ICSI (2627). The incidence of birth defects was statistically different, with 2.5% (32/1280) in IMSI and 4.5% (119/2627) in ICSI (RR=0.59; 95% CI=0.40-0.87; p=0.007). The results demonstrated that IMSI decreased the incidence of structural defects compared to ICSI - 2.2% (18/830) vs. 3.8% (78/2049) - in a statistically significant manner (RR=0.58; 95%CI=0.35-0.96; p=0.04). No significant difference was observed in chromosomal abnormalities (Trisomy 13; 18; 21 and Triple X) between children conceived after IMSI (8/830) or ICSI (19/2049) (RR=1.07; 95%CI=0.47-2.43; p=0.87). Conclusions IMSI seems to be an effective tool at reducing the incidence of structural defects compared to ICSI. However, IMSI does not change the incidence of chromosomal abnormalities.
- Published
- 2021